PRAX · Praxis Precision Medicines, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | - | $302.0K | $357.0K | $431.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $77.99M | - | $65.80M | $63.01M | $60.81M | - | $41.88M | $27.26M | $26.98M | - |
| SG&A | $27.87M | - | $12.56M | $13.06M | $13.92M | - | $15.26M | $10.59M | $15.33M | - |
| Total Operating Expenses | $105.86M | - | $78.36M | $76.07M | $74.73M | - | $57.14M | $37.84M | $42.32M | - |
| D&A | $39.0K | - | - | - | $47.0K | - | - | - | $112.0K | - |
| Operating Income | ($105.86M) | - | ($78.36M) | ($76.07M) | ($74.73M) | - | ($56.84M) | ($37.49M) | ($41.89M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($92.56M) | - | ($73.93M) | ($71.13M) | ($69.30M) | - | ($51.91M) | ($32.68M) | ($39.55M) | - |
| EPS - Basic | ($3.20) | - | ($3.36) | ($3.31) | ($3.29) | - | ($2.75) | ($1.74) | ($2.84) | - |
| EPS - Diluted | ($3.20) | - | ($3.36) | ($3.31) | ($3.29) | - | ($2.75) | ($1.74) | ($2.84) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $536.33M | $357.33M | $149.53M | $157.41M | $165.57M | $215.37M | $168.65M | $145.14M | $151.98M | $81.30M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $31.16M | $24.63M | $30.82M | $28.83M | $22.91M | $12.53M | $15.01M | $8.20M | $9.40M | $5.82M |
| Current Assets | $797.77M | $610.91M | $273.84M | $306.58M | $333.57M | $404.37M | $360.05M | $356.72M | $211.80M | $84.88M |
| Total Assets | $1.46B | $937.91M | $396.39M | $452.83M | $478.74M | $483.11M | $416.26M | $441.06M | $250.41M | $87.95M |
| Current Liabilities | $50.24M | $59.77M | $52.88M | $48.61M | $39.52M | $37.55M | $32.86M | $20.62M | $18.79M | $15.75M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $50.24M | $59.77M | $52.88M | $48.61M | $39.52M | $37.66M | $33.59M | $21.96M | $20.73M | $18.28M |
| Stockholders' Equity | $1.41B | $878.14M | $343.50M | $404.22M | $439.21M | $445.45M | $382.67M | $419.10M | $229.68M | $69.67M |
| Retained Earnings | ($1.23B) | ($1.14B) | ($1.05B) | ($977.16M) | ($906.04M) | ($836.74M) | ($778.06M) | ($726.15M) | ($693.47M) | ($653.92M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($86.15M) | - | - | - | ($53.01M) | - | - | - | ($20.86M) | - |
| Investing Cash Flow | ($344.27M) | - | - | - | ($51.06M) | - | - | - | ($91.22M) | - |
| Financing Cash Flow | $609.43M | - | - | - | $54.27M | - | - | - | $182.76M | - |
| CapEx | $0 | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($86.15M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | -18819.5% | -10500.8% | -9718.3% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -9692.3% | - |
| Net margin | - | - | - | - | - | - | -17188.7% | -9153.2% | -9177.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.93 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | 13867.9% | 7635.9% | 6260.8% | - |
| SG&A / Revenue | - | - | - | - | - | - | 5051.7% | 2965.0% | 3557.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.3% | - | -18.7% | -15.7% | -14.5% | - | -12.5% | -7.4% | -15.8% | - |
| Return on equity | -6.6% | - | -21.5% | -17.6% | -15.8% | - | -13.6% | -7.8% | -17.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 15.88 | 10.22 | 5.18 | 6.31 | 8.44 | 10.77 | 10.96 | 17.30 | 11.27 | 5.39 |
| Quick ratio | 15.88 | 10.22 | 5.18 | 6.31 | 8.44 | 10.77 | 10.96 | 17.30 | 11.27 | 5.39 |
| Cash ratio | 10.68 | 5.98 | 2.83 | 3.24 | 4.19 | 5.74 | 5.13 | 7.04 | 8.09 | 5.16 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.04 | 1.07 | 1.15 | 1.12 | 1.09 | 1.08 | 1.09 | 1.05 | 1.09 | 1.26 |
| Liabilities / Assets | 0.03 | 0.06 | 0.13 | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.08 | 0.21 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.6x | - | 3.4x | 2.2x | 1.8x | - | 2.8x | 1.9x | 3.7x | - |
| P / S | - | - | - | - | - | - | 3598.1x | 2180.9x | 1968.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -100.0% | -100.0% | -100.0% | - | -35.5% | -54.3% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -41.7% | - | -37.9% | -102.9% | -78.4% | - | -122.7% | -7.2% | -10.0% | - |
| Net income growth (YoY) | -33.6% | - | -42.4% | -117.7% | -75.2% | - | -110.7% | 4.8% | -5.6% | - |
| EPS growth (YoY) | 2.7% | - | -22.2% | -90.2% | -15.8% | - | -1427.8% | -255.1% | -300.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 221.0% | 97.1% | -10.2% | -3.5% | 91.2% | 539.4% | 341.1% | 296.8% | 256.3% | -8.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$8.55M totalReportable Segment$8.55M · 100.0%
Product / service
$8.60M totalLicense$8.60M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Praxis Precision Medicines against the 5 most active filers in the same SIC group.